°áÀå¾Ï¿¡¼ 5-Fluorouracil-based º¸Á¶Ç×¾ÏÈÇпä¹ýÀÇ Ä¡·á¹ÝÀÀ ¿¹ÃøÀÎÀڷνá Á¡¾×¼º ¼±¾ÏÀÇ ÀÇÀÇ
Mucinous Histology as a Predictive Marker of 5-Fluorouracil-based Adjuvant Chemotherapy for Colon Cancer
°Á¤Çö, ¹ÚÀ±¾Æ, ¼Õ½Â±¹, ÀÌ°¿µ, ¹Îº´¼Ò, Á¶Àåȯ, ±è³²±Ô,
¼Ò¼Ó »ó¼¼Á¤º¸
°Á¤Çö ( Kang Jeong-Hyun )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹ÚÀ±¾Æ ( Park Yoon-Ah )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¼Õ½Â±¹ ( Sohn Seung-Kook )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÀÌ°¿µ ( Rhee Kang-Young )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹Îº´¼Ò ( Min Byung-Soh )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¶Àåȯ ( Cho Jang-Hwan )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è³²±Ô ( Kim Nam-Kyu )
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
KMID : 0356720090250040241
Abstract
Purpose: The aim of this study was to evaluate the value of mucinous histology as a predictive marker of 5-Fluorouracil (FU)-based adjuvant chemotherapy in stage II, III colon cancer.
Methods: Between January 1995 and December 2004, 987 patients who underwent curative resections for stage II, III sporadic colon cancer were classified into two groups, a mucinous carcinoma (MC) group and a non-mucinous carcinoma (NMC) group, based on the histology of the primary tumor. The differences in their clinicopathological characteristics and the prognostic impact of 5-FU-based adjuvant chemotherapy for various tumor histologies were analyzed.
Results: Of the 987 patients, MCs accounted for 6.8% (68 patients). MCs were more frequently located in the Rt. Colon (P<0.001) and were more frequently seen in young patients (less than 40 yr old) (P=0.028). The 5-yr survival rates between MC and NMC did not show any statistically significant difference. Patients, including both MC and NMC patients, who received 5-FU-based chemotherapy, revealed a better overall survival rate than patients with no adjuvant chemotherapy. In the multivariate analysis for the prognosis in NMC patients, 5-FU-based adjuvant chemotherapy, initial negative nodal status, and preoperative CEA <5 ng/mL were statistically significant prognostic factors (P values: <0.001, <0.001, and <0.001, respectively). In contrast, there was no statistically independent significance of 5-FU-based adjuvant chemotherapy in MC patients.
Conslusion: In stage II and stage III sporadic colon cancer patients, response to 5-FU-based adjuvant chemotherapy in MC patients might be poor than it is in NMC patients.
Å°¿öµå
Á¡¾×¼º ¼±¾Ï;º¸Á¶Ç×¾ÏÈÇпä¹ý;°áÀå¾Ï
Mucinous carcinoma;Adjuvant chemotherapy;Colon cancer
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸